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When rubella occurs in a pregnant woman it can result in
fetal death, premature delivery, or a constellation of birth
defects known as congenital rubella syndrome (CRS). Ru-
bella and CRS have been nearly eliminated in the United
States. However, most crew members on cruise ships which
dock at US ports are from developing countries which do
not routinely vaccinate against rubella. Rubella outbreaks
have occurred among crew members, potentially putting at
risk pregnant crew members and passengers.
OBJECTIVE: To compare the costs of two interventions:
screen all crew members and vaccinate those found to be
susceptible to rubella versus vaccinate all crew members.
METHODS: A decision tree was created to compare the
two options. We used estimates of US private sector costs
for MMR vaccine, screening tests and costs of treating
adverse reactions. Data on susceptibility rates, and the
probabilities of adverse events were used in the model.
RESULTS: The model showed that it would cost $28 per
crew member to screen first and then vaccinate suscepti-
ble crew members versus $27 per crew member to vacci-
nate all crew members without screening. The three most
important variables in this analysis were the cost of the
vaccine, the cost of the screening test, and the rubella sus-
ceptibility rate of the crew members.
CONCLUSION: Using US costs, it is cheaper for cruise
lines to vaccinate all employees, rather than screen and
vaccinate only those who are susceptible. This model can
be modified for different cruise lines with specific suscep-
tibility rates and for vaccines which cruise lines may con-
sider administering to employees, such as varicella and
influenza vaccines.
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Therapy compliance is critical to the successful control of
diabetes. Poor control of diabetes often results in changes
in therapy, including switching to another agent or addi-
tion of concomitant therapy.
OBJECTIVE: The primary purpose of this study was to
determine whether compliance influenced the likelihood
of changes in diabetic therapy among newly diagnosed
diabetic patients.
METHODS: Pharmacy claims data were used to identify
newly diagnosed diabetic patients and evaluate compli-
ance from January 1995 through June 1997. Newly diag-
nosed diabetics were identified as those having a pre-
scription claim for an oral hypoglycemic agent in January
1996 with no diabetic claim in the previous 12 months.
Switching was identified as change to another oral hy-
poglycemic agent. Concomitant was defined as those pa-
tients who had additional therapy added to their mono-
therapy regimen. Cox proportional hazards was used to
estimate the influence of compliance on the likelihood of
changes in therapy controlling for patient age, gender,
and oral hypoglycemic agent.
RESULTS: The results suggest that those patients who
are more compliant are more likely to have concomitant
therapy added to their regimen (OR  1.69; 95% CI
1.60–1.79) compared to those least compliant. The op-
posite relationship was found for switching where those
most compliant were 22–38% less likely to switch ther-
apy compared to the least compliant group.
CONCLUSIONS: Compliance does play a role in changes
to therapy among diabetic patients. Disease severity may
play a role in explaining the results found. For those pa-
tients who had additional therapy added to their regi-
men, it appears that in spite of their good compliance,
their disease was not being controlled appropriately re-
sulting in the addition of concomitant therapy.
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OBJECTIVE: The aim of this study was to determine the
percentage of anti-hypertensive drugs documented in med-
ical records that appeared in managed care pharmacy
claims.
METHODS: Study subjects were incident hypertensive pa-
tients identified by: 1) at least one claim with an ICD-9 di-
agnosis code of hypertension and at least one claim for
an anti-hypertensive drug; or 2) at least two claims with
an ICD-9 diagnosis code of hypertension, preceded by a
6-month treatment-free period. Nurse abstractors reviewed
medical records for newly initiated or continuing anti-
hypertensive drugs (ACE inhibitors, angiotensin II recep-
tor blockers, beta-blockers, calcium channel blockers,
and diuretics). To determine whether these drugs were
filled, we reviewed pharmacy claims for a 12-month pe-
riod after the subject’s initial anti-hypertensive drug claim.
Drugs were “filled as intended” if a pharmacy claim for
the same drug was identified, and filled within 7 days prior
to, or 30 days after, the date of the notation in medical
records.
RESULTS: Medical records were abstracted for 563 pa-
tients, with 2205 notations of newly initiated or continu-
ing anti-hypertensive drugs. Of these, 1209 (54.8%)
pharmacy claims had fill dates that appeared to have
been “filled as intended.” The median “days supplied”
for these fills was 30 days, with a mode of 30 days.
CONCLUSION: In this population, 54.8% of anti-hyper-
tensive drugs noted in medical records appeared to have
been “filled as intended” based on pharmacy claims data.
Given a median of 30 “days supplied” for anti-hyperten-
